Persistent headache and chronic daily headache after COVID-19: a prospective cohort study

被引:0
|
作者
Carvalho, Larissa Clementino Leite Sa [1 ]
da Silva, Priscila Aparecida [2 ]
Rocha, Pedro Augusto Sampaio [1 ,3 ]
机构
[1] Univ Pernambuco UPE, Hosp Univ Oswaldo Cruz, Recife, PE, Brazil
[2] Univ Fed Pernambuco UFPE, Ctr Ciencias Med, Sci Initiat Fellowships Inst Program CNPq PROPESQ, Recife, PE, Brazil
[3] Univ Fed Pernambuco UFPE, Ctr Ciencias Med, Div Neuropsychiat, Rua Gen Joaquim Inacio 830,Sala 1412, BR-50070495 Recife, PE, Brazil
来源
KOREAN JOURNAL OF PAIN | 2024年 / 37卷 / 03期
关键词
COVID-19; Headache; Headache Disorders; Secondary; New Daily Persistent Headache; Pain; Post; Acute COVID-19 Syndrome; Prospective Studies; Risk Factors; POST-CRANIOTOMY HEADACHE;
D O I
10.3344/kjp.24046
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Little is known about the frequency and impact of the persistent headache and about the incidence of chronic daily headache (CDH) after coronavirus disease 2019 (COVID-19). The aim of this prospective cohort study was to assess the incidence, risk factors, characteristics, and impact of CDH in patients with COVID-19. Methods: In the first stage, 288 patients were interviewed by telephone after the acute phase of COVID-19. Subsequently, 199 patients who presented headache were reinterviewed at least one year after COVID-19. Headaches that persisted beyond the acute phase of COVID-19 for three or more months and presented frequency >= 45 days over the first three months were considered to be CDH. Results: One hundred and twenty-three patients were included, 56% were females; median age: 50 years (25th and 75th percentile: 41;58). The headache persisted beyond the acute phase of COVID-19 in 52%, and 20.3% had CDH (95% confidence interval: 13.6-28.2). Individuals who previously had headaches and who had headaches of greater intensity during the acute phase were at higher risk of developing CDH. The group with CDH included more females, greater impact of headache, more persistence of headache beyond the 120th day of COVID-19 and less throbbing headache than did the other individuals whose headache persisted. Conclusions: Patients who had COVID-19 had a high incidence of CDH. Previous headache and greater intensity of headache were associated with higher risk of CDH.
引用
收藏
页码:247 / 255
页数:9
相关论文
共 50 条
  • [21] Phenotype of new daily persistent headache: subtypes and comparison to transformed chronic daily headache
    Sanjay Cheema
    Anker Stubberud
    Khadija Rantell
    Parashkev Nachev
    Erling Tronvik
    Manjit Matharu
    The Journal of Headache and Pain, 24
  • [22] Persistent symptoms and spirometric abnormalities after COVID-19: A prospective cohort study
    Suri, T.
    Mohan, A.
    Mittal, S.
    Hadda, V
    Madan, K.
    Nath, S.
    Srivastava, G.
    Kumar, S.
    Shaji, S.
    Guleria, R.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [24] Prevalence of New Daily Persistent Headache in the General Population. The Akershus Study of Chronic Headache
    Grande, R.
    Aaseth, K.
    Lundqvist, C.
    Russell, M.
    HEADACHE, 2011, 51 (04): : 655 - 655
  • [25] New daily persistent headache (NDPH) in the general population. The Akershus study of chronic headache
    Grande, R. B.
    Aaseth, K.
    Lundqvist, C.
    Russell, M. B.
    EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 : 83 - 83
  • [26] Prevalence of new daily persistent headache in the general population. The Akershus study of chronic headache
    Grande, R. B.
    Aaseth, K.
    Lundqvist, C.
    Russell, M. B.
    CEPHALALGIA, 2009, 29 (11) : 1149 - 1155
  • [27] Comparison of the primary headache, COVID-19 headache, and COVID-19 immunization headache according to the phenotype in healthcare workers
    Gonzalez-Martinez, A.
    Panos Basterra, P.
    Dominguez Gallego, M.
    Somovilla, A.
    Martin Ramos, C.
    Morales Caballero, A.
    Lopez Guerrero, A.
    Garcia Cebrian, M.
    Vivancos, J.
    Gago-Veiga, A. B.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [28] Evaluation of Amitriptyline as a potential treatment for COVID-19 persistent headache
    Gonzalez-Martinez, A.
    Guerrero Peral, A. L.
    Gago Veiga, A. B.
    Sierra Mencia, A.
    Garcia-Azorin, D.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 108 - 108
  • [29] Evaluation of Amitriptyline as a potential treatment for COVID-19 persistent headache
    Gonzalez-Martinez, A.
    Guerrero Peral, A. L.
    Gago Veiga, A. B.
    Sierra Mencia, A.
    Garcia-Azorin, D.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 72 - 72
  • [30] Gray matter cortical changes in patients with persistent headache after COVID-19 infection: an exploratory study
    Planchuelo-Gomez, A.
    Garcia-Azorin, D.
    Guerrero Peral, A. L.
    Aja-Fernandez, S.
    Rodriguez, M.
    Moro, R.
    de Luis-Garcia, R.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 6 - 6